Oral & Macrocyclic Peptides – Part 2
Advancing the Frontier of Peptide Therapeutics
4/21/2027 - April 22, 2027 ALL TIMES PDT
Cambridge Healthtech Institute's Oral & Macrocyclic Peptides conferences (parts 1 & 2) are among the few peptide therapeutics conferences devoted to chemistry. The cornerstone of this two-part meeting is oral and/or macrocyclic peptide design and discovery, reflecting the next generation of peptide therapeutics and this conference's claim to fame as the industry's first macrocyclic-focused conference. However, peptide chemistry with broad peptide drug discovery and development implications, such as those spurred by the flurry of GLP1-related peptide activity, and downstream peptide development, will also be considered because the industry's frontier of peptide chemistry is relatively new and the scientists as well as the molecules are advancing together. Join us for this recently expanded two-part program to share progress, challenges, and solutions among leading medicinal and drug development peptide chemists, who are often one and the same (unlike the case for small molecules).
Preliminary Agenda

BEYOND PEPTIDE INHIBITORS

FEATURED PRESENTATION: Targeting Tumours with Peptide Radioconjugates

Photo of Jefferson D. Revell, PhD, Principal Scientist, BioPharmaceutical R&D and Discovery Sciences, AstraZeneca , Principal Scientist , BioPharmaceutical R&D and Discovery Sciences , AstraZeneca
Jefferson D. Revell, PhD, Principal Scientist, BioPharmaceutical R&D and Discovery Sciences, AstraZeneca , Principal Scientist , BioPharmaceutical R&D and Discovery Sciences , AstraZeneca

Peptide radioconjugates are a relatively new generation of oncology treatment, combining small format tumour-targeting with precision delivery of radiation. Among the many advantages of peptide radioconjugates such as high target specificity, rapid clearance, modularity, minimal immunogenicity and ease of manufacture, there are numerous physiological challenges to overcome. Within this talk I would like to discuss emerging design strategies to address such challenges arising during the development of peptide radioconjugates.

High-Throughput Synthesis of Covalent and Non-Covalent Peptides to Screen Challenging Protein Targets 

Photo of Christian Heinis, PhD, Associate Professor, Lab of Therapeutic Proteins & Peptides, EPFL Lausanne , Assoc Prof , Lab of Therapeutic Proteins & Peptides , EPFL Lausanne
Christian Heinis, PhD, Associate Professor, Lab of Therapeutic Proteins & Peptides, EPFL Lausanne , Assoc Prof , Lab of Therapeutic Proteins & Peptides , EPFL Lausanne
  • We developed nanoscale synthesis and high-throughput screening methods enabling the generation and evaluation of tens of thousands of macrocyclic peptides.
  • Our approach focuses on sub-kilodalton, low-polarity peptides designed to achieve membrane permeability, intracellular target engagement, and oral bioavailability.
  • The platform has enabled the discovery of potent inhibitors against challenging protein targets, including protein-protein interactions.
  • Recently, we expanded our methodology to generate and screen large libraries of covalent peptides, enabling the identification of inhibitors of particularly challenging protein–protein interactions, including Keap1–Nrf2 and ß-catenin–TCF4.?

Re-Stichting Degraded Peptide Hormones Using Small Molecules

Photo of Krishna Kumar, PhD, Robinson Professor of Chemistry, Tufts University , Robinson Professor , Chemistry , Tufts University
Krishna Kumar, PhD, Robinson Professor of Chemistry, Tufts University , Robinson Professor , Chemistry , Tufts University

Turning Peptides into Cell-Permeable Biologics

Paul A Bertin, CTO, Grove Biopharma Inc , CTO , Grove Biopharma Inc

DOWNSTREAM PEPTIDE CHEMISTRY

Triple Agonism at FGF21, GLP1, and GIP Receptors to Combat Obesity: Chemistry, Scalability, and CMC Implications

Photo of Florence Brunel, PhD, Senior Principal Scientist, Novo Nordisk Inc. , Senior Principal Scientist , Novo Nordisk
Florence Brunel, PhD, Senior Principal Scientist, Novo Nordisk Inc. , Senior Principal Scientist , Novo Nordisk

We will explore the design of a triple agonist combining FGF21, GLP-1, and GIP activities for the treatment of obesity. We will highlight the rationale for integrating complementary mechanisms and discuss peptide chemistry considerations, including molecular design, chemical modifications, and half-life extension. Broader considerations around synthesis, scalability, and developability will illustrate how discovery decisions can anticipate downstream needs and support the successful progression of complex peptide therapeutics toward clinical development.

Manufacturing Challenges of Tirzepatide

Stephanie R. Coffin, PhD, Senior Director, Eli Lilly and Company , Sr Dir , Eli Lilly & Co

Formulation and Delivery Considerations in Early Drug Discovery for Oral Peptides

Photo of Tahnee J. Dening, PhD, Principal Scientist, Genentech Inc. , Principal Scientist , Genentech Inc
Tahnee J. Dening, PhD, Principal Scientist, Genentech Inc. , Principal Scientist , Genentech Inc

PLENARY SESSIONS

PLENARY KEYNOTE

PLENARY KEYNOTE

Photo of Gwenn Hansen, PhD, CSO, Nurix Therapeutics, Inc. , Chief Scientific Officer , Research , Nurix Therapeutics Inc
Gwenn Hansen, PhD, CSO, Nurix Therapeutics, Inc. , Chief Scientific Officer , Research , Nurix Therapeutics Inc

PLENARY PANEL: INSIGHTS FROM VENTURE CAPITALISTS

Panel Moderator:

PANEL DISCUSSION:
VC Insights on Drug Discovery Trends

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation , Chief Innovation Officer , Frontier Medicines Corporation

Panelists:

James Edwards, PhD, Venture Partner, Samsara BioCapital , Venture Partner , Samsara BioCapital

Jamie Kasuboski, PhD, Partner, Luma Group , Partner , Luma Group

KT Moortgat, PhD, Managing Partner & Founder, Dalena Capital , Managing Partner & Founder , Dalena Capital

Sonia Setayesh, PhD, Partner, Civilization Ventures , Partner , Civilization Ventures

Chris Smith, PhD, CSO Partner Team, Curie.Bio , VP CSO Partner Team , Drug Discovery , Curie.Bio

Daniella Tedesco, Partner & Co-Founder, NextRound Philanthrophy , Co-Founder , NextRound Philanthrophy


For more details on the conference, please contact:
Anjani Shah, PhD
Senior Conference Director
Cambridge Healthtech Institute
(+1) 781-247-6252
Email: ashah@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com


Register Early for Maximum Savings

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides


Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners